A Phase 2 interventional study of Baricitinib and Placebo in Atopic Dermatitis, sponsored by Eli Lilly and Company. Completed at 13 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-17.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing baricitinib in Dermatitis, Atopic — 1 open to participants now, 1 under way, none of them phase 3. baricitinib · Dermatitis, Atopic.
Among the 11 studies testing baricitinib in Dermatitis, Atopic, this one is the 9th largest by enrollment, is the only one that started in 2016, is the only one in phase 2, and was the 1st registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →1 of the 11 studies testing baricitinib in Dermatitis, Atopic is open now, in 1 country. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 12–120
By country, each count listing its studies:
baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 1 started in 2016.
This study's enrollment of 124 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 440 across the 11 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 3 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
30 studies in Dermatitis, Atopic by Eli Lilly and Company: 1 open now, 2 under way, 2 of them phase 3. Of 28 finished, 25 (89%) have results posted.
Among the 30 studies in Dermatitis, Atopic by Eli Lilly and Company, this one is the 24th largest by enrollment, is the only one that started in 2016, is one of 5 in phase 2, and was the 2nd registered.
Eli Lilly and Company’s Dermatitis, Atopic studies by the year they started, since 2013.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing baricitinib in Dermatitis, Atopic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 30 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and effectiveness of Baricitinib in eczema.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have moderate-to-severe Atopic Dermatitis (AD), as determined by all of the following:
Exclusion Criteria:
Are currently experiencing or have a history of:
Currently experiencing or have a history of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administered once daily in multiple oral dose cohorts for 16 weeks (Triamcinolone 0.1% topical also permitted)
Drug: Baricitinib · Drug: Triamcinolone (Optional)
Administered orally once daily, for 16 weeks (Triamcinolone 0.1% topical also permitted)
Drug: Placebo · Drug: Triamcinolone (Optional)
Administered orally
Also known as: LY3009104, INCB028050
Administered orally
Administered topically
Percentage of Participants With a 50% or Greater Reduction in the Eczema Area and Severity Index (EASI 50)
The EASI 50, defined as ≥ 50% reduction from baseline in EASI score, assesses extent of disease based on dividing the skin into 4 regions (head/neck, trunk, upper limbs, and lower limbs) and measures the following clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3.The EASI confers a maximum score of 72 with 0 = clear; 0.1 -1 = almost clear; 1.1 -7 = mild; 7.1 - 21 = moderate; 21.1 - 50 = severe; 50.1 - 72 = very severe.
Time frame: Week 16
Change From Baseline in the EASI at Week 16
The Eczema Area and Severity Index (EASI) assesses extent of disease based on dividing the skin into 4 regions (head/neck, trunk, upper limbs, and lower limbs) and measures the following clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3.The EASI confers a maximum score of 72 with 0 = clear; 0.1 -1 = almost clear; 1.1 -7 = mild; 7.1 - 21 = moderate; 21.1 - 50 = severe; 50.1 - 72 = very severe. Change from baseline were analyzed with a Mixed-effect Model Repeated Measure (MMRM) with fixed effects for treatment, visit, country, and the treatment-by-visit interaction, plus baseline and baseline-by-visit included as covariates.
Time frame: Baseline, Week 16
Percentage Change From Baseline in the EASI at Week 16
The Eczema Area and Severity Index (EASI) assesses extent of disease based on dividing the skin into 4 regions (head/neck, trunk, upper limbs, and lower limbs) and measures the following clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3.The EASI confers a maximum score of 72 with 0 = clear; 0.1 -1 = almost clear; 1.1 -7 = mild; 7.1 - 21 = moderate; 21.1 - 50 = severe; 50.1 - 72 = very severe. Changes from baseline were analyzed with an MMRM with fixed effects for treatment, visit, country, and the treatment-by-visit interaction, plus baseline and baseline-by-visit included as covariates.
Time frame: Baseline, Week 16
Change From Baseline in the Scoring Atopic Dermatitis (SCORAD) at Week 16
The SCORAD index uses the rule of nines to assess disease extent and evaluates five clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation and (5) lichenification. SCORAD also assesses subjective symptoms of pruritus and sleep loss with Visual Analogue Scales (VAS) where 0 is no itch (or sleeplessness) and 10 is the worst imaginable itch (or sleeplessness). These three aspects: extent of disease (A: 0-102), disease severity (B: 0-18) and subjective symptoms (C:0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103 where 0 = no disease and 103 = severe disease. Changes from baseline were analyzed with an MMRM with fixed effects for treatment, visit, country, and the treatment-by-visit interaction, plus baseline and baseline-by-visit included as covariates.
Time frame: Baseline, Week 16
Change From Baseline in the Investigator's Global Assessment (IGA) at Week 16
The IGA consists of a 6-point severity scale to measure characteristics of erythema, infiltration, papulation, oozing and crusting as guidelines for the overall severity assessment. The scale ranges from clear to very severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, 4 = severe disease and 5 = very severe disease).
Time frame: Baseline, Week 16
Change From Baseline in the Dermatologic Life Quality Index (DLQI) at Week 16
The DLQI is a simple, participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". For all questions, if unanswered the question is scored as "0". Totals range from 0 to 30 (less to more impairment). Changes from baseline in DLQI score were analyzed with an MMRM with fixed effects for treatment, time, country, and the treatment-by-visit interaction, plus baseline and baseline-by-visit were included as covariates.
Time frame: Baseline, Week 16
Change From Baseline in the Itch Numerical Rating Scale (NRS) at Week 16
The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by circling the number that best describes the worst level of itching in the past 24 hours. Changes from baseline were analyzed with an MMRM with fixed effects for treatment, time, country, and the treatment-by-visit interaction, plus baseline and baseline-by-visit were included as covariates.
Time frame: Baseline, Week 16
Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Baricitinib
Pharmacokinetics (PK): Maximum serum concentration (Cmax) of Baricitinib
Time frame: Week (Wk) 0: Predose, 15-30 minutes (min) postdose; Wk 4: 1.5 - 4 hour (hr) postdose; Wk 8: 4 - 8 hr postdose; Wk 12: Predose; Wk 16: 30 - 90 min postdose.
| Milestone | Placebo | 2 mg Baricitinib | 4 mg Baricitinib |
|---|---|---|---|
| Started | 49 | 37 | 38 |
| Received at least one dose of study drug | 49 | 37 | 38 |
| Completed | 29 | 25 | 26 |
| Not completed | 20 | 12 | 12 |
| Withdrew: Adverse event | 5 | 3 | 6 |
| Withdrew: Protocol violation | 1 | 1 | 1 |
| Withdrew: Withdrawal by subject | 3 | 2 | 4 |
| Withdrew: Lack of efficacy | 9 | 4 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Withdrew: Met exclusion criteria | 0 | 1 | 0 |
The EASI 50, defined as ≥ 50% reduction from baseline in EASI score, assesses extent of disease based on dividing the skin into 4 regions (head/neck, trunk, upper limbs, and lower limbs) and measures the following clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3.The EASI confers a maximum score of 72 with 0 = clear; 0.1 -1 = almost clear; 1.1 -7 = mild; 7.1 - 21 = moderate; 21.1 - 50 = severe; 50.1 - 72 = very severe.
| percentage of participants | Placebo | 2 mg Baricitinib | 4mg Baricitinib |
|---|---|---|---|
| Percentage of Participants With a 50% or Greater Reduction in the Eczema Area and Severity Index (EASI 50) | 37 | 57 | 61 |
The Eczema Area and Severity Index (EASI) assesses extent of disease based on dividing the skin into 4 regions (head/neck, trunk, upper limbs, and lower limbs) and measures the following clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3.The EASI confers a maximum score of 72 with 0 = clear; 0.1 -1 = almost clear; 1.1 -7 = mild; 7.1 - 21 = moderate; 21.1 - 50 = severe; 50.1 - 72 = very severe. Change from baseline were analyzed with a Mixed-effect Model Repeated Measure (MMRM) with fixed effects for treatment, visit, country, and the treatment-by-visit interaction, plus baseline and baseline-by-visit included as covariates.
| units on a scale | Placebo | 2 mg Baricitinib | 4mg Baricitinib |
|---|---|---|---|
| Change From Baseline in the EASI at Week 16 | -10.84 ± 1.62 | -16.44 ± 1.72 | -16.04 ± 1.72 |
The Eczema Area and Severity Index (EASI) assesses extent of disease based on dividing the skin into 4 regions (head/neck, trunk, upper limbs, and lower limbs) and measures the following clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3.The EASI confers a maximum score of 72 with 0 = clear; 0.1 -1 = almost clear; 1.1 -7 = mild; 7.1 - 21 = moderate; 21.1 - 50 = severe; 50.1 - 72 = very severe. Changes from baseline were analyzed with an MMRM with fixed effects for treatment, visit, country, and the treatment-by-visit interaction, plus baseline and baseline-by-visit included as covariates.
| units on a scale | Placebo | 2 mg Baricitinib | 4mg Baricitinib |
|---|---|---|---|
| Percentage Change From Baseline in the EASI at Week 16 | -45.87 ± 5.85 | -64.19 ± 6.20 | -64.69 ± 6.21 |
The SCORAD index uses the rule of nines to assess disease extent and evaluates five clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation and (5) lichenification. SCORAD also assesses subjective symptoms of pruritus and sleep loss with Visual Analogue Scales (VAS) where 0 is no itch (or sleeplessness) and 10 is the worst imaginable itch (or sleeplessness). These three aspects: extent of disease (A: 0-102), disease severity (B: 0-18) and subjective symptoms (C:0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103 where 0 = no disease and 103 = severe disease. Changes from baseline were analyzed with an MMRM with fixed effects for treatment, visit, country, and the treatment-by-visit interaction, plus baseline and baseline-by-visit included as covariates.
| units on a scale | Placebo | 2 mg Baricitinib | 4mg Baricitinib |
|---|---|---|---|
| Change From Baseline in the Scoring Atopic Dermatitis (SCORAD) at Week 16 | -11.89 ± 2.88 | -23.87 ± 3.03 | -26.54 ± 2.97 |
The IGA consists of a 6-point severity scale to measure characteristics of erythema, infiltration, papulation, oozing and crusting as guidelines for the overall severity assessment. The scale ranges from clear to very severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, 4 = severe disease and 5 = very severe disease).
| units on a scale | Placebo | 2 mg Baricitinib | 4mg Baricitinib |
|---|---|---|---|
| Change From Baseline in the Investigator's Global Assessment (IGA) at Week 16 | -0.9 ± 0.69 | -1.4 ± 1.31 | -1.3 ± 1.01 |
The DLQI is a simple, participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". For all questions, if unanswered the question is scored as "0". Totals range from 0 to 30 (less to more impairment). Changes from baseline in DLQI score were analyzed with an MMRM with fixed effects for treatment, time, country, and the treatment-by-visit interaction, plus baseline and baseline-by-visit were included as covariates.
| units on a scale | Placebo | 2 mg Baricitinib | 4mg Baricitinib |
|---|---|---|---|
| Change From Baseline in the Dermatologic Life Quality Index (DLQI) at Week 16 | -6.27 ± 0.82 | -6.89 ± 0.89 | -7.96 ± 0.86 |
The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching is indicated by circling the number that best describes the worst level of itching in the past 24 hours. Changes from baseline were analyzed with an MMRM with fixed effects for treatment, time, country, and the treatment-by-visit interaction, plus baseline and baseline-by-visit were included as covariates.
| units on a scale | Placebo | 2 mg Baricitinib | 4mg Baricitinib |
|---|---|---|---|
| Change From Baseline in the Itch Numerical Rating Scale (NRS) at Week 16 | -1.72 ± 0.44 | -2.61 ± 0.47 | -2.22 ± 0.46 |
Pharmacokinetics (PK): Maximum serum concentration (Cmax) of Baricitinib
| nanogram per milliliter (ng/mL) | 2 mg Baricitinib | 4mg Baricitinib |
|---|---|---|
| Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Baricitinib | 18.5 ± 70.0 | 37.7 ± 38.9 |
Collected over Baseline to end of study (up to 5 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/49 (0%) | 0/49 (0%) | 14/49 (28.6%) |
| 2 mg Baricitinib | 0/37 (0%) | 2/37 (5.4%) | 13/37 (35.1%) |
| 4mg Baricitinib | 0/38 (0%) | 1/38 (2.6%) | 19/38 (50%) |
| Event | Placebo | 2 mg Baricitinib | 4mg Baricitinib |
|---|---|---|---|
| BronchitisInfections and infestations | 0/49 | 1/37 | 0/38 |
| CellulitisInfections and infestations | 0/49 | 1/37 | 0/38 |
| Staphylococcal infectionInfections and infestations | 0/49 | 1/37 | 0/38 |
| EczemaSkin and subcutaneous tissue disorders | 0/49 | 1/37 | 0/38 |
| Large intestine polypGastrointestinal disorders | 0/49 | 0/37 | 1/38 |
| Event | Placebo | 2 mg Baricitinib | 4mg Baricitinib |
|---|---|---|---|
| Blood creatine phosphokinase increasedInvestigations | 1/49 | 1/37 | 5/38 |
| HeadacheNervous system disorders | 0/49 | 2/37 | 5/38 |
| NasopharyngitisInfections and infestations | 2/49 | 1/37 | 4/38 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 5/49 | 3/37 | 2/38 |
| LymphopeniaBlood and lymphatic system disorders | 3/49 | 0/37 | 1/38 |
| CellulitisInfections and infestations | 3/49 | 1/37 | 0/38 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/49 | 2/37 | 0/38 |
| NauseaGastrointestinal disorders | 0/49 | 2/37 | 0/38 |
| Staphylococcal infectionInfections and infestations | 0/49 | 2/37 | 0/38 |
| Subcutaneous abscessInfections and infestations | 1/49 | 0/37 | 2/38 |
All participants who received at least one dose of study drug.
| Age, Continuous(years) | Placebo | 2 mg Baricitinib | 4mg Baricitinib | Total |
|---|---|---|---|---|
| Mean | 37.3 ± 13.49 | 40.0 ± 14.38 | 36.4 ± 14.47 | 37.8 ± 14.03 |
| Sex: Female, Male(Participants) | Placebo | 2 mg Baricitinib | 4mg Baricitinib | Total |
|---|---|---|---|---|
| Female | 25 | 15 | 16 | 56 |
| Male | 24 | 22 | 22 | 68 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 2 mg Baricitinib | 4mg Baricitinib | Total |
|---|---|---|---|---|
| Hispanic or Latino | 4 | 4 | 6 | 14 |
| Not Hispanic or Latino | 45 | 33 | 32 | 110 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | 2 mg Baricitinib | 4mg Baricitinib | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 16 | 8 | 9 | 33 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 2 | 3 |
| Black or African American | 7 | 9 | 9 | 25 |
| White | 23 | 20 | 18 | 61 |
| More than one race | 2 | 0 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo | 2 mg Baricitinib | 4mg Baricitinib | Total |
|---|---|---|---|---|
| United States | 42 | 31 | 32 | 105 |
| Japan | 8 | 6 | 6 | 20 |
| Median EASI Total Score(units on a scale) | Placebo | 2 mg Baricitinib | 4mg Baricitinib | Total |
|---|---|---|---|---|
| Median | 22.1 (12.0 to 70.3) | 22.1 (12.2 to 72.0) | 19.5 (12.2 to 71.4) | 21.2 (12.0 to 72.0) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
The record gives a start of Feb 2016, a primary completion of Feb 2017 and a completion of Mar 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2018, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baricitinib